Capitalization 7.75B 590B P/E ratio 2024 *
-8.55x
P/E ratio 2025 * -36.7x
Enterprise value 7.72B 588B EV / Sales 2024 *
11.1x
EV / Sales 2025 * 8.35x
Free-Float
35.05%
Yield 2024 *
0.04%
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-9.78%
1 week-15.48%
Current month-15.48%
1 month+23.47%
More quotes
1 week
47.04
Extreme 47.0448
62.20
1 month
36.80
Extreme 36.8
77.00
Current year
22.89
Extreme 22.89
77.00
1 year
22.89
Extreme 22.89
77.00
3 years
22.89
Extreme 22.89
77.00
5 years
22.89
Extreme 22.89
77.00
10 years
22.89
Extreme 22.89
77.00
More quotes
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-9.78%-15.48% - - 7.75B
+0.52%-3.49%+8.08%-31.66%46.02B
-2.04%-3.37%+11.08%-7.66%44.31B
-1.87%-6.06%+22.50%+24.98%31.68B
+1.70%-5.81%+30.16%-27.17%29.63B
-0.75%-5.83%-32.66%-82.51%28.02B
-1.78%-6.07%+17.85%+15.31%25.05B
-1.25%-4.93%+54.74%+63.96%15.38B
-1.22%-3.38%-5.32%-44.27%11.34B
-3.36%-5.50%+25.35%+72.02%10.39B
Average -1.98%-5.71%+14.64%-1.89% 24.96B
Weighted average by Cap. -1.14%-4.80%+12.60%-10.37%
See all sector performances
2024 *2025 *
Net sales 697M 53.1B 929M 70.76B
Net income -757M -57.68B -232M -17.68B
Net Debt -22.73M -1.73B 6.55M 499M
More financial data * Estimated data
Logo Tempus AI, Inc
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
Employees
1,500
More about the company
Date Price Change Volume
06/09/24 50.19 $ -9.78% 1,465,169
05/09/24 55.63 $ +3.53% 949,359
04/09/24 53.74 $ +3.16% 797,115
03/09/24 52.09 $ -12.28% 1,083,964
30/08/24 59.38 $ +2.54% 715,263

Delayed Quote Nasdaq, September 06, 2024 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
50.19USD
Average target price
46.00USD
Spread / Average Target
-8.35%
Consensus